echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The IRd total oral regimen assists in continuous treatment and the analysis of elderly MM cases

    The IRd total oral regimen assists in continuous treatment and the analysis of elderly MM cases

    • Last Update: 2022-09-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    Multiple myeloma (MM) is a clonal plasma cell disease that occurs in old age and is still incurable




    • Graduate

    • Attending physician, Department of Hematology, Affiliated Hospital of Jining Medical College

    • Graduated from the First Affiliated Hospital of Soochow University

    • Member of the Hematology Professional Committee of Shandong Non-public Medical Institutions Association

    • Member of the Cell Clinical Research Professional Committee of Shandong Biomedical Engineering Society

    • Publications: three papers in SCI and one in core journals



    • Director of the Department of Hematology, Affiliated Hospital of Jining Medical College

    • Doctor of Medicine Chief Physician Master Supervisor

    • Hematology Branch of Chinese Medical Association is a member of the 8th Youth Committee

    • Member of the Experimental Diagnostics Group of the Hematology Branch of the Chinese Medical Association

    • Member of the Anti-Leukemia Alliance of the Chinese Society of Clinical Oncology (CSCO).


    • Member of hematology branch of Shandong Medical Association

    • Deputy Leader of the Transplantation Group of the Hematology Branch of Shandong Medical Association

    • Member of the Standing Committee of the Hematology Branch of Shandong Medical Doctor Association


    • The patient was an elderly patient with frail MM with anemia, colon, and ovarian disease, and partial remission (PR) was achieved after induction of therapy from dexamethasone


    • It can be seen that IRd can be used as a treatment option



    Clinical studies have shown that the IRd all-oral regimen can improve the depth of remission in PATIENTS with MM, prolong the survival without progression (PFS)2, and is easy to use and highly accessible, which helps to reduce the discontinuation



    References

    [1] Dimopoulos MA, et al.


    [2] Manda S, et al.


    Edited: Moon Reviewer: Janet Typesetting: moly Executive: moly 

    Click "Read the original article" to see the full content


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.